Down 37% in 4 Weeks, Here's Why Aquestive Therapeutics (AQST) Looks Ripe for a Turnaround

Core Viewpoint - Aquestive Therapeutics (AQST) has experienced a significant decline of 37% over the past four weeks, but it is now in oversold territory, suggesting a potential for a turnaround as analysts expect better earnings than previously predicted [1]. Group 1: Technical Analysis - The Relative Strength Index (RSI) is a key technical indicator used to determine if a stock is oversold, with readings below 30 indicating oversold conditions [2]. - AQST's current RSI reading is 20.13, indicating that the heavy selling pressure may be exhausting itself, which could lead to a reversal in the stock's trend [5]. Group 2: Fundamental Analysis - Analysts covering AQST have shown strong agreement in raising earnings estimates, with the consensus EPS estimate increasing by 0.4% over the last 30 days, which typically correlates with price appreciation [7]. - AQST holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a near-term turnaround [8].